Member log in

Biomedical co.'s ambitious plans, ACC levies shrouded in mystery, why investors should study Fonterra’s NZX settlement

A local sleeper medical technology company has ambitious plans to move into commercial production, and won’t rule out an initial public offering.

Reporter David Williams looks into how the up and coming tech company are developing a smart device to remotely monitor how people with asthma and other respiratory diseases are coping with treatment, in today’s National Business Review print edition.

In other news, Wellington-based reporter Rob Hosking looks at why ACC levies are being shrouded in mystery by the government, with Business New Zealand saying the costly levy is no longer needed.

AMP talks on why it won’t be touching mortgage funds again for a while, after finally paying out bondholders more than $173 million from a frozen fund.

Lobby Watch takes a magnifying glass to pro-GM lobbyist Dr William Rolleston, looking at how the well-connected scientist and vice-president of Federated Farmers could fracture the $31 billion farming industry. 

Economic columnist Neville Bennett counts the cost of the “grim reaper” GFC, saying New Zealand will dangerously continue to ride the back of the Chinese dragon in future.

A guest column by Steve Nicholson deciphers Indonesia’s presidential election, and company director Victoria Carter passes on her tips.

Briefly:

  • Shoeshine examines why investors should carefully study Fonterra’s denial of disclosure breach.
  • Rich listers are leading Christchurch’s first major post-earthquake anchor project.
  • A special report on how to put together the perfect conference.

All this and more in today’s National Business Review. Out now.

Comments and questions
1

ACC has enough investment income to practically eliminate levies. To date only a token reduction is being offered.

Whats deperately needed is competition and remove the legislative protection.